Yeah, sadly, the market doesn't seem that interested. And yet SPT, who hasn't made any decent revenue, is up almost 14% on yesterday's closing price.
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress